
IN8BIO (INAB) Stock Forecast & Price Target
IN8BIO (INAB) Analyst Ratings
Bulls say
IN8bio Inc is exhibiting a positive outlook due to the encouraging efficacy results of its gamma-delta T cell product candidate, INB-100, particularly in preventing relapse in high-risk acute myeloid leukemia (AML) patients post-haploidentical stem cell transplantation, with a remarkable 100% overall survival rate at one year. The company’s ongoing study is expanding to include a multi-center 25-patient cohort, which is expected to further validate these results and enhance the product's market potential as enrollment is anticipated to complete by 2025. Additionally, INB-100 is demonstrating a favorable safety profile, with no reported treatment-related deaths or serious adverse events, underscoring its potential for further clinical advancement and commercial viability.
Bears say
The financial outlook for IN8bio reflects increased caution, as evidenced by the reduced 12-month price target from $8.00 to $6.00. Despite the potential shown by INB-619 in preclinical studies, the overall development pipeline may be hindered by challenges in transitioning candidates from preclinical to clinical stages. These factors raise concerns about the company's ability to effectively advance its gamma-delta T cell therapies in a competitive biopharmaceutical landscape.
This aggregate rating is based on analysts' research of IN8BIO and is not a guaranteed prediction by Public.com or investment advice.
IN8BIO (INAB) Analyst Forecast & Price Prediction
Start investing in IN8BIO (INAB)
Order type
Buy in
Order amount
Est. shares
0 shares